Previous studies indicate that treatment with chemotherapeutic agents and targeted therapies, such as RTKIs, increased COX-2 expression in bladder cancer cells, glioma cancer stem cells, non-small cell lung cancer, and oral squamous cell carcinoma cells in vitro [29–33]. Here, PTGS2 is linked to non-small cell lung carcinoma.